Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"OMAN","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elevar Therapeutics and Taiba Middle East FZ LLC Partner to Commercialize Apealea\u00ae in the Middle East and North Africa Region","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"OMAN","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Insmed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiba Middle East Announces a Commercialization and Distribution Agreement With Insmed for ARIKAYCE in the Countries of GCC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"OMAN","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aspargo\u2019s Global Footprint Grows With Middle East Expansion, Disrupting the Erectile Dysfunction Market With Oral Spray","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"OMAN","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Taiba Healthcare

    Menu

    Taiba Healthcare

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Taiba Healthcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Oman
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aspargo’s Global Footprint Grows With Middle East Expansion, Disrupting the Erectile Dysfunction Market With Oral Spray

              Details:

              The license grants Taiba the exclusive right and license to market, promote, and distribute Viagra as Sildenafil Spray in the territory described in the license, which covers Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, Oman, Lebanon, Egypt, and Iraq.

              Lead Product(s): Sildenafil Citrate

              Therapeutic Area: Psychiatry/Psychology Product Name: Viagra

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Aspargo Laboratories

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Taiba Healthcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Oman
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Taiba Middle East Announces a Commercialization and Distribution Agreement With Insmed for ARIKAYCE in the Countries of GCC

              Details:

              Under the terms of the agreement, taiba will be responsible for the named patient supply program with intent to commercialize ARIKAYCE in the region following receipt of marketing authorization(s) in the territory.

              Lead Product(s): Amikacin

              Therapeutic Area: Infections and Infectious Diseases Product Name: Arikayce

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Insmed

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement June 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Taiba Healthcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Oman
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Elevar Therapeutics and Taiba Middle East FZ LLC Partner to Commercialize Apealea® in the Middle East and North Africa Region

              Details:

              Tiba will be responsible for managing named-patient requests through which physicians can legally and ethically prescribe Apealea for patients prior to commercial availability, commercialize and distribute the product throughout the Middle East and North African region.

              Lead Product(s): Paclitaxel,Carboplatin

              Therapeutic Area: Oncology Product Name: Apealea

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Elevar Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Taiba Healthcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Oman
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States

              Details:

              The distribution agreement is focused on both ONPATTRO® and GIVLAARI®, the first-ever commercialized RNAi therapeutics, as well as another late-stage therapy in development for Primary Hyperoxaluria Type 1.

              Lead Product(s): Patisiran

              Therapeutic Area: Genetic Disease Product Name: Onpattro

              Highest Development Status: Approved Product Type: Cell and Gene therapy

              Recipient: Alnylam Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY